Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of SLU-PP-332 and SR-9011 — mechanism, side effects, legal status, and pricing.
SLU-PP-332 is a small-molecule (non-peptide) pan-agonist of estrogen-related receptors ERRα/β/γ developed at Saint Louis University. Studied preclinically as an exercise mimetic in rodents, it has no human clinical data and is NOT FDA-approved. Sold only as a grey-market research chemical.
SR-9011 is a synthetic small-molecule REV-ERB (Rev-erbα/β) agonist — not a peptide — studied preclinically as a circadian/metabolic modulator. It has no human data of any kind, no regulatory approval, and is WADA-prohibited at all times. Note: it is frequently confused with "Stenabolic," which is properly its analog SR9009, not SR-9011.
SLU-PP-332
SR-9011
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
SLU-PP-332
SR-9011
COA corpus from Disclosed Labs — independently tested batches only.
SLU-PP-332
26
COAs
99.5%
Avg purity
11
Labs
SR-9011
1
COAs
96.8%
Avg purity
1
Labs
Billon et al. (ACS Chemical Biology, 2023) reported that SLU-PP-332 in sedentary mice increased treadmill endurance, enhanced slow-twitch fiber content, boosted mitochondrial biogenesis, and conferred resistance to high-fat-diet weight gain without exercise training. A follow-up (Billon et al., J Pharmacol Exp Ther, 2024) showed benefits in mouse metabolic-syndrome models. Developed at Saint Louis University (Burris/Walker/Elgendy groups). Rodent/preclinical data ONLY — no human clinical trials have been initiated. Not FDA-approved; not a peptide.
In diet-induced obese mice (intraperitoneal dosing), SR-9011/SR9009 increased energy expenditure, reduced fat mass, and improved dyslipidemia and hyperglycemia (Solt et al., Nature 2012). Human liver microsome work identified 14 metabolites but no half-life, and the authors caution against human extrapolation. There are no registered human trials of SR-9011; no human safety, dose, or pharmacokinetic data exist.
SLU-PP-332 and SR-9011 are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs